Wells Fargo raised the firm’s price target on Kymera Therapeutics to $30 from $26 and keeps an Equal Weight rating on the shares. There was not much new in the Q4 update from the recent I&I R&D day on January 9, but the company now has plenty of cash to move forward its early-stage pipeline, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KYMR:
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics sees cash runway into 1H27
- Kymera Therapeutics reports Q4 EPS (25c), consensus (40c)
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics initiated with a Peer Perform at Wolfe Research